InvestSMART

Argent Biopharma Limited (ASX:RGT)

ALERT: Price-sensitive ASX Announcement for RGT
Current share price for RGT : $0.022 -0.012 (-35.29%)+
Announcement
Release
23 Oct 2026 8:15AM
Price at Release
$0.034
Full Release
download
Summary
Argent Biopharma Limited (ASX: RGT) reported for the quarter ended 30 September 2026 that it has refined its strategy to focus on immune modulation and inflammatory disease after globally licensing CannEpil®, with priorities spanning commercialisation of CimetrA® and the newly licensed NLC antiviral portfolio, support for CannEpil® licensing/manufacturing/regulatory activities, and further research into chronic inflammation and healthy ageing biology; during the quarter Argent secured an exclusive royalty-bearing worldwide licence outside China to commercialise NLC’s Tollovir, Tollovid and NutraVir antiviral applications, while preserving existing US Tollovid rights and acquiring NutraVir inventory for US$1.00, and it also finalised the CannEpil® global licence to Splash Beverage Group, now Endovia Health Sciences, with US$5.5 million upfront consideration satisfied via forgiveness of Mercer Street Global Opportunity Fund convertible notes, allowing Argent to retain CannEpil® intellectual property ownership, cost-plus manufacturing rights and royalty streams of 15% on human therapeutic sales and 10% on veterinary applications; Endovia then advanced a US veterinary programme with FDA-CVM INAD File No. 14145 for cancer-related pain in companion animals. Financially, the Appendix 4C shows net operating cash outflow of A$734,000, including A$149,000 in staff costs, A$48,000 in research and development, A$507,000 in administration and corporate costs, A$22,000 in advertising and marketing and A$14,000 in operating costs, offset by A$10,000 customer receipts, while financing inflows included A$600,000 from convertible debt under the Company’s A$11 million facility, resulting in quarter-end cash of A$11,000; related party payments totalled A$73,000 for directors’ fees, unused funding under the facility was A$7.4 million, estimated funding runway was 10.1 quarters, and after quarter end Argent entered unsecured loan facilities totalling US$500,000 for working capital.
Key Points
  • Argent Biopharma released its September 2026 Quarterly Activity Report and Appendix 4C on 23 October 2026.
  • The company refined its strategy to focus on immune modulation and inflammatory disease following the global licensing of CannEpil®.
  • RGT-CA91980 was identified as the lead internally developed programme, supported by CimetrA®, ArtemiC history and the preclinical NanoBodies programme.
  • Argent entered an exclusive royalty-bearing licence with NLC to commercialise Tollovir, Tollovid and NutraVir antiviral applications worldwide excluding China.
  • Existing TolloHealth LLC rights to Tollovid products in the United States were preserved under the NLC arrangement.
  • Argent will acquire substantially all existing NutraVir inventory for US$1.00.
  • Royalties payable to NLC are 12% on the first US$2.5 million of cumulative net sales, 9% on the next US$2.5 million and 6% thereafter for each product.
  • Argent finalised a binding framework granting Endovia Health Sciences an exclusive global licence to commercialise CannEpil®.
  • The US$5.5 million upfront CannEpil® consideration was satisfied through forgiveness of Mercer Street Global Opportunity Fund convertible notes, removing the company’s principal secured liability.
  • Argent retained ownership of CannEpil® intellectual property and continues manufacturing on a cost-plus basis with up to a 20% margin.
  • Argent receives a 15% perpetual royalty on human therapeutic CannEpil® sales and a 10% perpetual royalty on veterinary applications.
  • Endovia commenced a US veterinary development programme for CannEpil® and FDA-CVM established INAD File No. 14145 on 26 August 2026.
  • The veterinary programme initially targets cancer-related pain in companion animals, beginning with canine oncology.
  • Net cash used in operating activities during the quarter was A$734,000.
  • Quarterly operating cash outflows included A$149,000 in staff costs, A$48,000 in research and development and A$507,000 in administration and corporate costs.
  • Argent received A$600,000 from convertible debt securities during the quarter under its A$11 million financing facility.
  • Cash and cash equivalents at 30 September 2026 were A$11,000.
  • Unused financing facilities at quarter end were A$7.4 million, implying an estimated funding runway of 10.1 quarters.
  • Payments to related parties totalled A$73,000 and related to directors’ fees.
  • After quarter end, Argent entered unsecured loan facilities totalling US$500,000 to support working capital.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.